Aim: To determine the effect of waiting time for radiotherapy on the overall survival of patients with glioblastoma.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults [1] . Standard treatment consists of maximal surgical resection followed by radiation therapy with concurrent and adjuvant temozolomide. However, the progonosis remains extremely poor, with a median survival of 14.6 months [2] . The optimal interval between surgery and chemoradiotherapy is unknown. However, for most patients, we start RT within 2 to 4 weeks following surgical resection. Waiting times for radiotherapy (RT) have become longer over the last 20 years in many countries. [3, 4, 5] . The principal cause of this problem is the increasing demand of RT. This increasing demand is due of on an increasing incidence of cancer and growing role of RT in cancer management [6] . Treatment delay has been examined at different sites including head and neck cancer [3, 7, 8, 9] and breast cancer [10, 11, 12, 13] . The failure to demonstrate a convincing effect of delay in waiting time may be due to many factors including patient selection, physician treatment practices and unmeasured tumor variables such as volume and grade. The actual evidence for minimizing the delay to RT is conflicting. Some series have been published suggesting that delaying RT can worsen survival [14, 15, 21] , while others actually suggest that a short delay may be beneficial [16] . The goal of the current study is to determine the effect on survival of treatment delay for patients with glioblastoma.
METHODES Patients and tumors
Eligible patients had supratentorial glioblastoma, any age and received a postoperative radiotherapy with or without chemotherapy. The accrual period was from 1 Janvier 2010 to 31 December 2015.
Treatment
Patients were treated with RT using modern treatment planning techniques. Radiotherapy consisted of fractionated focal irradiation at a dose of 2 Gy or 3 Gy per fraction given once daily five days per week, for a total dose of 60 Gy or 30 Gy respectively. Radiotherapy was planned with dedicated computed tomography (CT) and three-dimensional planning systems; conformal radiotherapy was delivered with linear accelerators with nominal energy of 6 MV.
Waiting time
Two waiting time variables were examined:
1. time from biopsy to the start of radiotherapy; this represents the most accurate estimate of waiting time. BWT 2. time from presentation to radiotherapy department to the start of radiotherapy; this is a more clinically relevant measure as it directly relates to departmental resources and work conditions. PWT
Statistical methods
The survival curves were calculated by the method of Kaplan and Meier and compared using the log-rank test. A Cox proportional hazards model was used to clarify independent predictive factor in multivariate analysis. Statistical significance was defined as a pvalue of < 0.05. The variables examined were age, performance status, extent of surgery, and the addition of temozolomide to radiotherapy. In addition, the two definitions of waiting times were included in the subset selection process.
RESULTS
There were 102 eligible patients with a median followup of 9 months.
Patients
The median patient age was 56 years with a range from 18 to 82 years. There were 66 males and 36 females.
Surgery
All patients have a biopsy or debulking surgery and postoperative radiotherapy. The surgical procedures were as follows: biopsy only in 34 (33.3%) patients and total resection in 68 (66.6%) patients.
Waiting times
Median times and ranges of waiting times from biopsy and presentation time to radiotherapy were 52 days (11±110 days) and 32 days (4±80 days) respectively.
Treatment 78 patients received radiotherapy alone (60 Gy, 2 Gy/fraction for 63 patients and 30 Gy, 3 Gy/fraction for 15 patients) and 24 patients received radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
Survival
The median of the whole group was 8 months. Table 1 shows the median survival for treatment pronostic variables (age, surgery, chemoterapy and waiting times). In univariate analysis (Table 2 ) older age and absence of total resection were all significantly associated with reduction in overall survival. In multivariate analysis (Table 3) , only the absence of total resection was the variable significantly associated with reduced overall survival. 
DISCUSSION
Waiting times must affect outcome? While it would be scientifically preferable to perform a randomized trial to answer this question. It would be clinically and ethically unacceptable to do so. The question of waiting time effects can only be examined by retrospective studies. The limitations of retrospective studies are well known and include bias from selection, uncontrolled patient and tumour factors and physician treatment bias. Nevertheless, they remain the only tool available. The waiting time before irradiation is a recurring problem. It has been studied extensively for breast cancers and upper aerodigestive tract cancers [7] [8] [9] [10] [11] [12] [13] . But the literature concerning the effect of waiting time in brain tumors is rare [15, 17] . In multifactor analysis, overall survival was related to the nature of the macroscopically complete surgical resection. Starting from the doubling time published in the literature, 24 days for theoretical studies [18] and 48 to 88 days [19] for imaging studies, the tumors would have in the case of our study progressed from 50 to 500%. Macroscopically surgery could reduce the delay factor by limiting tumor volume before radiotherapy. However, it is not possible to study this factor in our study since most patients did not have postoperative imaging. The age did not appear significant in the multifactorial analysis, probably because the older patients were also the ones who received the lowest physical radiation dose compared to the classical protocol of 60 Gy in 30 fractions of 2Gy. Minniti has demonstrated that both standard (60 Gy in 30 daily fractions) and hypofractionated radiotherapy (30-40 Gy in 10-15 daily fractions) have been employed with a similar survival benefit [20] . We did not observe any significant difference in terms of overall survival. In addition, the cohort patients over 70 is probably too limited to to be able to definitively conclude. In our study, survival rate was not be affected by different waiting times. [15] . A comparable conclusion was published by Irwin et al. in a cohort of 172 patients. They showed that a delay of six weeks between surgery and the start of radiotherapy resulted in a loss of median overall survival of 11 weeks [21] . In the opposite way, Thomson et al. could not demonstrate the impact of delays between the first consultation in oncology and the beginning of the radiotherapy and between surgery and the beginning of radiotherapy in a serie of 40 patients with glioblastoma and treated by irradiation and temozolomide [22] . Also, Lopez et al. were unable to identify the role of the delay in overall survival of 60 patients treated for glioblastoma [23] .
CONCLUSION
It was not possible in this analysis to evidence of the impact of delays in initiating radiotherapy for patients with glioblastoma. However, it is out of the question to consider the lengthening of delays as acceptable. It should be remembered that the weeks during which patients waiting for the start of radiation therapy can be painful, especially if the symptoms are severe. This must push us to make the delay as short as possible.
